Esophageal Diseases  >>  sorafenib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sorafenib / Generic mfg.
NCT00917462: Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
2
35
US
Sorafenib, administered orally, CT/MRI
Memorial Sloan Kettering Cancer Center, Bayer
Esophageal Cancer, Gastroesophageal Junction Cancer
08/18
08/18

Download Options